AFRM could make an oversold bounce of $10 to $20, but let's look at the trend as a Real Money subscriber asks about the stock.
As M&A investments could hit $400 billion this year, watch for buys in health technology and data, biotech, pharma and medical devices.
Is a candle lighting the way higher?
The longer stock picking doesn't work then the greater the opportunities will be when it does work.
The Fed has to take some action: No matter how you slice it, 7% CPI is an unacceptable inflation rate. Here's my take on inflation and what's ahead.
There are signs that a reversal may be brewing and many small-caps and biotechnology names are weak again.
The homebuilder will report it's quarterly results after Wednesday's market close.
The impact of inflation, increased demand as the pandemic fades and the threat of reduced supply all give reason to believe in the sector.
The markets have responded to the wash-out of sellers in the prior session as noted by 'hammer' formations.
Traders comfortable buying shares in a Brazilian company could probe the long side of GGB at current levels.